Zobrazeno 1 - 10
of 696
pro vyhledávání: '"Lan SHAO"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract We conducted this cross-sectional study to investigate the independent associations between lipid metabolites and osteoporotic fractures among participants aged 40–69 years from the UK Biobank. Serum lipid, lipoprotein levels and nuclear m
Externí odkaz:
https://doaj.org/article/f13320ae441e44ffa31683ff2dd7d7c0
Autor:
Lan Shao, Haoran Yu, Mengyun Wang, Lu Chen, Boshu Ji, Tong Wu, Xiangqi Teng, Mu Su, Xiao Han, Weikai Shi, Xin Hu, Ziwen Wang, Hongjuan He, Guiping Han, Yan Zhang, Qiong Wu
Publikováno v:
Cell Death and Disease, Vol 15, Iss 8, Pp 1-20 (2024)
Abstract Super-enhancers are a class of DNA cis-regulatory elements that can regulate cell identity, cell fate, stem cell pluripotency, and even tumorigenesis. Increasing evidence shows that epigenetic modifications play an important role in the path
Externí odkaz:
https://doaj.org/article/a2ae6e85b9bb40549537f4e9a90992ed
Publikováno v:
Heliyon, Vol 10, Iss 11, Pp e32260- (2024)
Programmed death-1 (PD-1) acts as a T cell checkpoint and is important in controlling T cell exhaustion. Blocking the intercommunication across PD-1 and PD-L1 is promising for advanced lung cancer treatment. However, the response rate requires being
Externí odkaz:
https://doaj.org/article/bf1ee0450a7d438fb470c5fcd23fff27
Autor:
Chao Liang, Juan Zhou, Yongjie Wang, Yin Sun, Jin Zhou, Lan Shao, Zhichang Zhang, Wangjun Yan, Zhiyan Liu, Yang Dong
Publikováno v:
Journal of Bone Oncology, Vol 44, Iss , Pp 100517- (2024)
Background: Osteosarcoma, the most common primary malignant bone tumor, is currently treated with surgery combined with chemotherapy, but the limited availability of targeted drugs contributes to a poor prognosis. Identifying effective therapeutic ta
Externí odkaz:
https://doaj.org/article/75c7370b979f4234a8d8a35f34df2985
Autor:
Zhen Hu, Xin Wang, Conglin Hong, Congyi Zheng, Linfeng Zhang, Zuo Chen, Haoqi Zhou, Yixin Tian, Xue Cao, Jiayin Cai, Runqing Gu, Ye Tian, Lan Shao, Zengwu Wang
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-12 (2023)
Abstract Background A workplace-based primary prevention intervention be an effective approach to reducing the incidence of hypertension (HTN). However, few studies to date have addressed the effect among the Chinese working population. We assessed t
Externí odkaz:
https://doaj.org/article/fe3c0b494b24441dae8735894b416bef
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-3 (2023)
Externí odkaz:
https://doaj.org/article/998d8b4e4de34fe6820543ac3f154b14
Autor:
Yilin Huang, Linfeng Zhang, Zengwu Wang, Xin Wang, Zuo Chen, Lan Shao, Ye Tian, Congying Zheng, Lu Chen, Haoqi Zhou, Xue Cao, Yixin Tian, Runlin Gao, for the China Hypertension Survey investigators
Publikováno v:
BMC Public Health, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Metabolic syndrome (MetS) is characterized by a cluster of signs of metabolic disturbance and has caused a huge burden on the health system. The study aims to explore the prevalence and characteristics of MetS defined by different
Externí odkaz:
https://doaj.org/article/94bd87e1cc1f4f2687a418031a2a6713
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-17 (2022)
Abstract In the course of chemotherapy for breast cancer, doxorubicin (DOX) is one of the most commonly prescribed agents. However, it has been recognized as clinically circumscribed on account of its poor selectivity and toxic reactions to normal ti
Externí odkaz:
https://doaj.org/article/7c54bc9f24cd4be7b140f5e59bd16d3b
Autor:
Xiaodong Gu, Zhiyong Shi, Lan Shao, Yuxin Zhang, Yiping Zhang, Zhengbo Song, Wenxian Wang, Guangyuan Lou
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Advanced non-squamous non-small cell lung cancer (NS-NSCLC) patients without driver gene mutations are usually treated with immune checkpoint inhibitors (ICIs) plus pemetrexed as maintenance therapy after first-line ICIs plus 4–
Externí odkaz:
https://doaj.org/article/0e27735ed3c249f09d030e5eb4678ed4
Publikováno v:
BMC Pulmonary Medicine, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Anlotinib is a multitarget tyrosine kinase inhibitor for treating patients with advanced non-small cell lung cancer (NSCLC). We aimed to assess the efficacy and safety of anlotinib in elder patients with advanced NSCLC. Methods El
Externí odkaz:
https://doaj.org/article/58908db157074b2d94ee7fb8ad6d92ff